Given that few somatic mutations have been identified in NB patients (ALK, PHOX2B), the epigenome of NB tumors has recently been explored in order to identify critical enzymes as novel therapeutic targets for differentiation reprogramming. This evidence concerns the gene ALK and neuroblastoma.